Cited by 270Attention Deficit Hyperactivity DisorderObsessive-Compulsive Spectrum DisordersBehavioral and Psychological Studies

Meta-Analysis: Treatment of Attention-Deficit/Hyperactivity Disorder in Children With Comorbid Tic Disorders

Open access
Bloch, Michael H., Panza, Kaitlyn E., Landeros-Weisenberger, Angeli, Leckman, James F.·2009·Journal of the American Academy of Child & Adolescent Psychiatry

Abstract

Objective The Food and Drug Administration currently requires the package inserts of most psychostimulant medications to list the presence of a tic disorder as a contraindication to their use. Approximately half of children with Tourette's syndrome experience comorbid attention-deficit/hyperactivity disorder (ADHD). We sought to determine the relative efficacy of different medications in treating ADHD and tic symptoms in children with both Tourette's syndrome and ADHD.Method We conducted a PubMed search to identify all double-blind, randomized, placebo-controlled trials examining the efficacy of medications in the treatment of ADHD in the children with comorbid tics. We used a random effects meta-analysis with standardized mean difference as our primary outcome to estimate the effect size of pharmaceutical agents in the treatment of ADHD symptoms and tics.Results Our meta-analysis included nine studies involving 477 subjects. We assessed the efficacy of six medications-dextroamphetamine, methylphenidate, alpha-2 agonists (clonidine and guanfacine), desipramine, atomoxetine, and deprenyl. Methylphenidate, alpha-2 agonists, desipramine, and atomoxetine demonstrated efficacy in improving ADHD symptoms in children with comorbid tics. Alpha-2 agonists and atomoxetine significantly improved comorbid tic symptoms. Although there was evidence that supratherapeutic doses of dextroamphetamine worsens tics, there was no evidence that methylphenidate worsened tic severity in the short term.Conclusions Methylphenidate seems to offer the greatest and most immediate improvement of ADHD symptoms and does not seem to worsen tic symptoms. Alpha-2 agonists offer the best combined improvement in both tic and ADHD symptoms. Atomoxetine and desipramine offer additional evidence-based treatments of ADHD in children with comorbid tics. Supratherapeutic doses of dextroamphetamine should be avoided.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/chi.0b013e3181b26e9f

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A recent meta-analysis indicated that treating ADHD in children with tic disorders is safe and effective.

    “A recent meta-analysis indicated that treating ADHD in children with tic disorders is safe and effective [276,277].”
  • In ADHD comorbid with tic disorders, supratherapeutic doses of dextroamphetamine should be avoided.

    “meta-analyses of stimulants and other ADHD medications in the treatment of ADHD comorbid with tic disorders concluded that supratherapeutic doses of dextroamphetamine should be avoided in this population.”

    From Advances in understanding and treating ADHD (2011) · cites this paper as [51]

  • In ADHD comorbid with tic disorders, methylphenidate gives the best control for ADHD.

    “These studies also indicated that methylphenidate gave the best control for ADHD and that α-2-agonists produced the best improvement in both tics and ADHD [51,52].”

    From Advances in understanding and treating ADHD (2011) · cites this paper as [51]

  • In ADHD comorbid with tic disorders, alpha-2-agonists produce the best improvement in both tics and ADHD.

    “These studies also indicated that methylphenidate gave the best control for ADHD and that α-2-agonists produced the best improvement in both tics and ADHD [51,52].”

    From Advances in understanding and treating ADHD (2011) · cites this paper as [51]

  • Several recent reviews indicate that stimulants are adequately safe in patients with both ADHD and tic disorders and should not be disregarded when planning treatment for ADHD in these individuals.

    “Several recent reviews [24, 119, 124] indicate that stimulants are adequately safe in patients with both ADHD and TD and should not be disregarded when planning treatment for ADHD in these individuals.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 1

  1. [31]Review Manager (RevMan) [computer program]. Version 4.2 for Windows 2003 Copenhagen The Nordic Cochrane Centre, The Cochrane Collaboration

Cited by

Sorted by citations

Authors
Bloch, M. H., Panza, K. E., Landeros-Weisenberger, A., & Leckman, J. F.
Affiliations
Yale University (US)
Corresponding author
Bloch, Michael H.
Venue
Journal of the American Academy of Child & Adolescent Psychiatry
Publisher
Elsevier BV
Published
2009-09
Volume
48
Issue
9
Pages
884-893
ISSN
0890-8567 (ISSN-L)
OpenAlex
W2001006163
Cited by
270
References
57
Citations by year
2026: 6 · 2025: 9 · 2024: 7 · 2023: 9 · 2022: 16 · 2021: 9 · 2020: 26 · 2019: 10 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 17 · 2014: 23 · 2013: 21 · 2012: 24
FWCI
15.00
Type
journal article
Language
en
Open access
Locations
  • Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Eli Lilly and Company
  • Yale University
  • American Psychiatric Institute for Research and Education
  • Child Study Center, Yale School of Medicine
  • National Institutes of Health
  • National Institute of Mental Health (K05MH076273, K23MH091240, T32MH018268)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
  • Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
Keywords
attention deficit hyperactivity disorder, Tourette syndrome, tic disorders, comorbidities, psychostimulants, methylphenidate, d-amphetamine, alpha-2 adrenergic agonists, clonidine, guanfacine, atomoxetine, desipramine, selegiline, supratherapeutic dosing, children
MeSH terms
Atomoxetine Hydrochloride, Contraindications, Adrenergic alpha-Agonists, Attention Deficit Disorder with Hyperactivity, Child, Dose-Response Relationship, Drug, Double-Blind Method, Tourette Syndrome, Humans, Methylphenidate, Propylamines, Psychotropic Drugs, Tic Disorders, Comorbidity, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review